GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

keverprazan   Click here for help

GtoPdb Ligand ID: 12653

Synonyms: Example 1 [WO2016119505A1] | Keprason®
Approved drug
keverprazan is an approved drug (China (2023))
Compound class: Synthetic organic
Comment: Keverprazan (hydrochloride) is a potassium ion-competitive acid blocker (P-CAB) [3], that was developed to decrease gastric acid production. P-CABs inhibit the gastric H+,K+-ATPase, and are therapeutic alternatives to long-used proton pump inhibitors [4].
P-CABs are an evolving class of drugs, the first of which to enter clinical use was revaprazan in 2007 (S Korea).

keverprazan is commercially available from our sponsors

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 6
Hydrogen bond donors 1
Rotatable bonds 10
Topological polar surface area 76.25
Molecular weight 432.51
XLogP 1.79
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES CNCC1=CN(C(=C1)C2=C(C=CC=C2)F)S(=O)(=O)C3=CC(=CC=C3)OCCCOC
Isomeric SMILES CNCC1=CN(C(=C1)C2=C(F)C=CC=C2)S(=O)(=O)C3=CC=CC(OCCCOC)=C3
InChI InChI=1S/C22H25FN2O4S/c1-24-15-17-13-22(20-9-3-4-10-21(20)23)25(16-17)30(26,27)19-8-5-7-18(14-19)29-12-6-11-28-2/h3-5,7-10,13-14,16,24H,6,11-12,15H2,1-2H3
InChI Key UDHVRDAZIAGHFG-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
References
1. Chen S, Liu D, Chen H, Liao A, Li F, Liu C, Li X, Li S, Zhang Y, Wang Y et al.. (2022)
The efficacy and safety of keverprazan, a novel potassium-competitive acid blocker, in treating erosive oesophagitis: a phase III, randomised, double-blind multicentre study.
Aliment Pharmacol Ther, 55 (12): 1524-1533. [PMID:35505467]
2. Kang C. (2023)
Keverprazan Hydrochloride: First Approval.
Drugs, 83 (7): 639-643. [PMID:37074491]
3. Qin Y, Koh S, Jin Q, Chen T, Jiang J. (2016)
Pyrrole sulfonyl derivative, and preparation method and medical use thereof.
Patent number: WO2016119505A1. Assignee: Jiangsu Kefeiping Medical Co., Ltd., Nanjing Kefeiping Shenghui Pharmaceutical Co., Ltd.. Priority date: 11/11/2015. Publication date: 04/08/2016.
4. Rawla P, Sunkara T, Ofosu A, Gaduputi V. (2018)
Potassium-competitive acid blockers - are they the next generation of proton pump inhibitors?.
World J Gastrointest Pharmacol Ther, 9 (7): 63-68. [PMID:30595950]
5. Tan ND, Liu XW, Liu CX, Li SB, Chen HH, Li X, Wu H, Liao AJ, Zhen YB, Shen PZ et al.. (2022)
Efficacy of keverprazan for duodenal ulcer: A phase II randomized, double-blind, parallel-controlled trial.
J Gastroenterol Hepatol, 37 (11): 2060-2066. [PMID:36068945]